Yahoo Finance

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...
Nasdaq

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

- Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ...
Business Wire

Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis

-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...
Yahoo Finance

Vertex (VRTX) to Buy ViaCyte to Speed Up VX-880 Program

Vertex Pharmaceuticals Incorporated VRTX has entered into an agreement to acquire ViaCyte, a private cellular therapy company, to accelerate the development of the VX-880 program in type I diabetes.
Nasdaq

Vertex To Initiate Phase 3 Program For Once-Daily Triple Combination Regimen In Cystic Fibrosis

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) said that it will initiate a phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 ...